## William Herrington

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11952740/publications.pdf

Version: 2024-02-01

623188 752256 2,952 21 14 20 citations g-index h-index papers 21 21 21 4364 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
2	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology,the, 2016, 4, 829-839.	5.5	234
3	Diabetes and Cause-Specific Mortality in Mexico City. New England Journal of Medicine, 2016, 375, 1961-1971.	13.9	207
4	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	0.8	82
5	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	0.7	49
6	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	2.1	42
7	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
8	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	1.3	30
9	Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review. Transplantation Reviews, 2015, 29, 139-144.	1.2	27
10	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
11	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	2.2	22
12	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	1.2	21
13	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	2.2	19
14	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
15	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK. JAMA Network Open, 2021, 4, e2139748.	2.8	15
16	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	2.6	13
17	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	3.0	10
18	Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150Â000 Mexican adults. European Journal of Preventive Cardiology, 2022, 29, 730-738.	0.8	8

#	Article	IF	CITATIONS
19	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
20	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. Journal of Clinical Epidemiology, 2020, 128, 148-156.	2.4	4
21	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	0.5	0